Evidence map›Paper›PMID 34253580›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021

Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network.

Guray Akturk, Edwin R Parra, Evisa Gjini, Ana Lako, J Jack Lee, Donna Neuberg, Jiexin Zhang, Shen Yao, Ilaria Laface, Anita Rogic and 13 more

Abstract readMulticenter Study
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. A Forgotten Principle in Immunocytochemistry: Optimal Dilution.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Guray Akturk *Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York.ORCID 0000-0001-7032-8085
Edwin R Parra *Translational Molecular Pathology-Dermatopathology Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9068-1636
Evisa GjiniCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-6951-9279
Ana LakoCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
J Jack LeeTranslational Molecular Pathology-Dermatopathology Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5469-9214
Donna NeubergDana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-2566-3145
Jiexin ZhangTranslational Molecular Pathology-Dermatopathology Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-9526-6730
Shen YaoTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York.
Ilaria LafaceTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York.
Anita RogicTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York.
Pei-Hsuan ChenDana-Farber Cancer Institute, Boston, Massachusetts.
Beatriz Sanchez-EspiridionTranslational Molecular Pathology-Dermatopathology Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Diane M Del ValleTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York.ORCID 0000-0001-6983-5362
Radim MoravecKelly Services; Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland.
Robert KindersLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Courtney HudgensTranslational Molecular Pathology-Dermatopathology Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8312-7485
Catherine WuDana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-3348-5054
Ignacio I WistubaTranslational Molecular Pathology-Dermatopathology Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Magdalena ThurinDivision of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland.
Stephen M HewittLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.
Scott RodigCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Sacha Gnjatic *Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, New York.ORCID 0000-0001-5643-9520
Michael T Tetzlaff *Translational Molecular Pathology-Dermatopathology Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas. michael.tetzlaff@ucsf.edu.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4M
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5M
Stanford Cancer Immune Monitoring and Analysis Center (CIMAC)U24CA224309 · NCI · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Holden T. Maecker · 2017 to 2026
$19.9M
Cancer Immune Monitoring and Analysis CenterU24CA224331 · NCI · DANA-FARBER CANCER INST · PI FRANK S HODI, Catherine Ju-Ying Wu · 2017 to 2026
$18.4M
Translational Cancer Immune Monitoring and Analysis Center (TCIMAC)U24CA224285 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Gheath Al-Atrash, Cara L Haymaker · 2017 to 2026
$16.7M
Experimental Pathology Laboratory (EPL)ZICBC011638 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2015 to 2025
$16.6M
Personalized Immunotherapy of Patients with Ovarian CancerP01CA190174 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SABBATINI, PAUL J, SPRIGGS, DAVID R · 2015 to 2019
$10.5M
Cancer Immunologic Data Commons (CIDC) Supplement RequestU24CA224316 · NCI · DANA-FARBER CANCER INST · PI CERAMI, ETHAN, MICHOR, FRANZISKA · 2017 to 2022
$6.8M
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9M
NCI NIH HHS HHSN261201600002CNCI NIH HHS P01 CA190174NCI NIH HHS P30 CA016672NCI NIH HHS P30 CA196521NCI NIH HHS P50 CA070907NCI NIH HHS U24 CA224285NCI NIH HHS U24 CA224309NCI NIH HHS U24 CA224316NCI NIH HHS U24 CA224319NCI NIH HHS U24 CA224331NIDDK NIH HHS U01 DK124165
6 · The paper itself

Abstract

purposeThe Cancer Immune Monitoring and Analysis Centers - Cancer Immunologic Data Commons (CIMAC-CIDC) network supported by the NCI Cancer Moonshot initiative was established to provide correlative analyses for clinical trials in cancer immunotherapy, using state-of-the-art technology. Fundamental to this initiative is implementation of multiplex IHC assays to define the composition and distribution of immune infiltrates within tumors in the context of their potential role as biomarkers. A critical unanswered question involves the relative fidelity of such assays to reliably quantify tumor-associated immune cells across different platforms. EXPERIMENTAL

designThree CIMAC sites compared across their laboratories: (i) image analysis algorithms, (ii) image acquisition platforms, (iii) multiplex staining protocols. Two distinct high-dimensional approaches were employed: multiplexed IHC consecutive staining on single slide (MICSSS) and multiplexed immunofluorescence (mIF). To eliminate variables potentially impacting assay performance, we completed a multistep harmonization process, first comparing assay performance using independent protocols followed by the integration of laboratory-specific protocols and finally, validating this harmonized approach in an independent set of tissues.

resultsData generated at the final validation step showed an intersite Spearman correlation coefficient (

conclusionsOur results support interchangeability of protocols and platforms to deliver robust, and comparable data using similar tissue specimens and confirm that CIMAC-CIDC analyses may therefore be used with confidence for statistical associations with clinical outcomes largely independent of site, antibody selection, protocol, and platform across different sites.

Indexed as

Biomarkers, TumorFluorescent Antibody TechniqueHumansImage Processing, Computer-AssistedMonitoring, ImmunologicNeoplasmsStaining and LabelingBiomarkers, Tumor

Identifiers

PMID34253580
PMCPMC9777693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.